Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion

Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis remains poor. Until recently, topotecan (a topoisomerase I inhibitor) was the only drug approved by the United States (US) F...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Millie, Padda, Sukhmani K., Weiss, Jared, Owonikoko, Taofeek K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475485/
https://www.ncbi.nlm.nih.gov/pubmed/34564806
http://dx.doi.org/10.1007/s12325-021-01909-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475485/
https://www.ncbi.nlm.nih.gov/pubmed/34564806
http://dx.doi.org/10.1007/s12325-021-01909-1

Ejemplares similares